Heparin Investigation Highlights Foreign Inspection Gap – Former FDA Officials
This article was originally published in PharmAsia News
Executive Summary
Members of Congress have jumped on the reported admission by U.S. FDA that it did not inspect a Changzhou City, China plant that provides active pharmaceutical ingredients for Baxter Healthcare's injectable heparin as a symbol of FDA's inability to adequately inspect pharmaceuticals manufactured abroad
You may also be interested in...
China Biologic Renews GMP Certification Under Stiffer SFDA GMP Rules
SHANGHAI- China Biologic Products has renewed its GMP certification for its production facility in Taian City in compliance with China State FDA's new, strict GMP standards, which took effect in January
China Biologic Renews GMP Certification Under Stiffer SFDA GMP Rules
SHANGHAI- China Biologic Products has renewed its GMP certification for its production facility in Taian City in compliance with China State FDA's new, strict GMP standards, which took effect in January
U.S. Mulls Registration Fees For Foreign Drug Manufacturers
In light of recent safety concerns about foreign-manufactured pharmaceutical products, members of the U.S. Congress are considering whether to introduce registration fees for foreign drug manufacturers exporting products to the U.S